

T-BET and EOMES sustain mature human NK cell identity and antitumor function

Pamela Wong, ... , Melissa M. Berrien-Elliott, Todd A. Fehniger

J Clin Invest. 2023;133(13):e162530. <https://doi.org/10.1172/JCI162530>.

Research Article

Immunology

Since the T-box transcription factors (TFs) T-BET and EOMES are necessary for initiation of NK cell development, their ongoing requirement for mature NK cell homeostasis, function, and molecular programming remains unclear. To address this, T-BET and EOMES were deleted in unexpanded primary human NK cells using CRISPR/Cas9. Deleting these TFs compromised in vivo antitumor response of human NK cells. Mechanistically, T-BET and EOMES were required for normal NK cell proliferation and persistence in vivo. NK cells lacking T-BET and EOMES also exhibited defective responses to cytokine stimulation. Single-cell RNA-Seq revealed a specific T-box transcriptional program in human NK cells, which was rapidly lost following T-BET and EOMES deletion. Further, T-BET⁻ and EOMES-deleted CD56^{bright} NK cells acquired an innate lymphoid cell precursor-like (ILCP-like) profile with increased expression of the ILC-3-associated TFs *RORC* and *AHR*, revealing a role for T-box TFs in maintaining mature NK cell phenotypes and an unexpected role of suppressing alternative ILC lineages. Our study reveals the critical importance of sustained EOMES and T-BET expression to orchestrate mature NK cell function and identity.

Find the latest version:

<https://jci.me/162530/pdf>



T-BET and EOMES sustain mature human NK cell identity and antitumor function

Pamela Wong,¹ Jennifer A. Foltz,¹ Lily Chang,¹ Carly C. Neal,¹ Tony Yao,¹ Celia C. Cubitt,¹ Jennifer Tran,¹ Samantha Kersting-Schadek,¹ Sathvik Palakurty,¹ Natalia Jaeger,¹ David A. Russler-Germain,¹ Nancy D. Marin,¹ Margery Gang,¹ Julia A. Wagner,¹ Alice Y. Zhou,¹ Miriam T. Jacobs,¹ Mark Foster,¹ Timothy Schappe,¹ Lynne Marsala,¹ Ethan McClain,¹ Patrick Pence,¹ Michelle Becker-Hapak,¹ Bryan Fisk,¹ Allegra A. Petti,² Obi L. Griffith,¹ Malachi Griffith,¹ Melissa M. Berrien-Elliott,¹ and Todd A. Fehniger^{1,3}

¹Department of Medicine, Division of Oncology, ²Department of Neurological Surgery, and ³Siteman Cancer Center, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.

Since the T-box transcription factors (TFs) T-BET and EOMES are necessary for initiation of NK cell development, their ongoing requirement for mature NK cell homeostasis, function, and molecular programming remains unclear. To address this, T-BET and EOMES were deleted in unexpanded primary human NK cells using CRISPR/Cas9. Deleting these TFs compromised *in vivo* antitumor response of human NK cells. Mechanistically, T-BET and EOMES were required for normal NK cell proliferation and persistence *in vivo*. NK cells lacking T-BET and EOMES also exhibited defective responses to cytokine stimulation. Single-cell RNA-Seq revealed a specific T-box transcriptional program in human NK cells, which was rapidly lost following T-BET and EOMES deletion. Further, T-BET- and EOMES-deleted CD56^{bright} NK cells acquired an innate lymphoid cell precursor-like (ILCP-like) profile with increased expression of the ILC-3-associated TFs *RORC* and *AHR*, revealing a role for T-box TFs in maintaining mature NK cell phenotypes and an unexpected role of suppressing alternative ILC lineages. Our study reveals the critical importance of sustained EOMES and T-BET expression to orchestrate mature NK cell function and identity.

Introduction

Natural killer (NK) cells are innate lymphoid cells important for responses against pathogens and malignant cells. They direct the immune response through production of cytokines and directly kill diseased target cells via cytotoxic granules and death receptors (1, 2). In recent years, NK cell therapies have emerged as a promising option for treating cancers because of their low toxicity profile and their potent ability to drive antitumor responses (3–5). NK cell products can be sourced from peripheral blood as well as differentiated from cord blood or induced pluripotent stem cells (6–8). Additional strategies to enhance NK cell function, such as inducing memory-like NK differentiation with cytokines (3, 5, 9–11), introducing tumor-targeting chimeric antigen receptors (12), or using NK cells in combination with tumor-targeting antibodies or

inhibitory checkpoint blockades, are now being tested in multiple clinical trials with promising results (6). Thus, understanding the fundamentals of mature NK cell biology will inform the nascent field of NK cell immunotherapy.

Studies in mice have shown that the T-box transcription factors (TFs) EOMES and T-BET are required for initiation of NK cell development, and their expressions persist in mature murine and human NK cells after development (13, 14). Constitutive, NK cell-specific knockout of EOMES or T-BET occurring at early stages of development results in a deficiency of mature NK cells (15, 16). In addition, T-BET also regulates mouse NK cell trafficking out of the bone marrow (17). However, because these models lack mature NK cells, the study of EOMES and T-BET in fully mature NK cells has not been feasible, and thus their ongoing importance to NK cell biology during maturity remains an open question in the field. Use of a tamoxifen-inducible NK cell-specific Cre mouse model revealed that EOMES was required for regulation of homeostasis and function of mature mouse NK cells, in a murine stage-specific fashion (18). Consistent with this, EOMES deletion in murine NK cells also impacted NK cell homeostatic turnover (19). Thus, while data related to EOMES and T-BET deficiency are emerging from inducible, conditional mouse models, our understanding of the importance of T-box TFs for mature human NK cell programs remains limited.

Most mechanistic studies of TFs in human NK cells to date have been performed in cell lines, NK cells differentiated *in vitro* from CD34⁺-derived hematopoietic stem cells, or NK cells that have been expanded *ex vivo* (20–22). While these models provide a starting point for study of mature human NK cell biology, these approaches do not recapitulate normal NK cell physiology. Recent-

Conflict of interest: TAF and MMBE have pending patents (15/983,275, 62/963,971, and PCT/US2019/060005) licensed to Wugen Inc. and have equity interest in, have consulted for, and have royalty interest in Wugen Inc. unrelated to this work. JAF has pending patents (WO 2019/152387, US 63/018,108) unrelated to the present work that are licensed to Kiadis and a monoclonal antibody unrelated to the present work licensed to EMD Millipore. MBH has a patent (US8895020B2) unrelated to the present work. Unrelated to this work, CCC has equity in Pionyr Immunotherapeutics, and DARG receives consulting fees from Cartography Inc. TAF reports research funding from the NIH during the conduct of the study; equity in and research funding and consulting fees from Wugen Inc.; research funding from ImmunityBio, HCW Biologics, and Affimed; consulting fees from Kiadis, Takeda, AI Proteins, Smart Immune, and Affimed; and other support from Indapta and OrcaBio, all unrelated to this work.

Copyright: © 2023, Wong et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.

Submitted: June 9, 2022; **Accepted:** May 19, 2023; **Published:** July 3, 2023.

Reference information: *J Clin Invest.* 2023;133(13):e162530.

<https://doi.org/10.1172/JCI162530>.

ly, a single case of a patient with inherited T-BET deficiency was reported, with the patient exhibiting a defect in the NK cell compartment, and a separate study overexpressed EOMES and T-BET in NK progenitor cells, thereby promoting NK cell differentiation (20, 23). While these studies suggest that EOMES and T-BET play a role in human NK cell development, evaluation of EOMES or T-BET genetic loss of function in mature human NK cells has not been reported. Further, since EOMES and T-BET have similar DNA binding motifs and may play redundant roles, examination of mature NK cells with combined EOMES and T-BET deficiency is needed to address this gap in our knowledge and elucidate T-box TFs' contribution to maintain NK cell molecular programs.

To address the importance of T-box TFs and their regulation of mature NK cell programs, we used CRISPR/Cas9 to genetically delete EOMES and T-BET expression in unexpanded, primary human NK cells. We hypothesized that beyond their roles in regulating NK development, EOMES and T-BET are critical for maintaining the NK cell functional programs that define NK cells, including proliferation, survival, cytotoxicity, and cytokine production. To define molecular mechanisms, we also used single-cell RNA-Seq and assay for transposase-accessible chromatin using sequencing (ATAC-Seq) to uncover key transcriptional and chromatin changes in mature human NK cells with deletion of EOMES and T-BET. These findings revealed a profound dependency on T-box TFs to maintain mature human NK cell function and identity.

Results

CRISPR editing deletes T-BET and EOMES in unexpanded primary human NK cells. Genetic manipulation of primary human NK cells has been a challenge in the field, limiting our ability to use loss or gain of function to mechanistically understand human NK cell biology. Peripheral blood NK cells were freshly isolated from healthy donors, purified to more than 95% by negative enrichment, cultured in low-dose IL-15 (required for NK cell survival), and electroporated with Cas9 mRNA along with sgRNA targeting *EOMES* or *TBX21* using the MaxCyte GT system (9). This approach achieved consistent deletion of EOMES and T-BET protein expression in both the CD56^{bright} and CD56^{dim} NK cell subsets without the need to expand them with high-dose cytokines or feeder cells (Supplemental Figure 1; supplemental material available online with this article; <https://doi.org/10.1172/JCI162530DS1>).

Since T-BET and EOMES have highly homologous DNA binding domains, deletion of one could result in compensation by the other (24, 25). To address their redundancy, both EOMES and T-BET were CRISPR-edited by simultaneous electroporation of *TBX21* and *EOMES* gRNAs, which successfully abrogated both EOMES and T-BET protein expression to generate double-knockout (DKO) NK cells (Figure 1, A–C). To discern between all cells that received the CRISPR gRNAs and the subset that were deficient for T-BET and EOMES at the protein level, “*T+E* edited” and “DKO” will be used, respectively. We observed no significant changes in *T+E* edited NK cell survival in vitro, in comparison with control cells that were CRISPR-edited with *TRAC* gRNA used as control, indicating that the two T-box TFs are not absolutely required for NK cell survival (Figure 1D). This approach of simultaneous T-BET and EOMES deletion then allows investigation of

the functional impact of naturally developed and mature primary human NK cells lacking these two T-box TFs.

EOMES and T-BET deletion does not affect short-term in vitro killing but impairs long-term in vitro killing. One hallmark of NK cell function is their ability to eliminate MHC class I-deficient tumor cells (1, 2). To assess the impact of T-box TF deficiency on NK cells' cytotoxic ability in a short-term assay, we sorted CD56^{bright} and CD56^{dim} NK cells 5 days after CRISPR editing, rested them overnight in low-dose IL-15, and then cocultured them with the MHC-I-deficient cell line K562 for 4–6 hours. In this short-term killing assay, there was no significant effect of T-box TF deficiency on NK cells' ability to kill K562 targets (Supplemental Figure 2A). This was expected because of the presence of granzyme B and perforin protein within preformed granules in the NK cells that result in immediate cytotoxicity. To test the effect of T-box TF deficiency in a longer-term in vitro cytotoxicity assay, we used the IncuCyte Imaging System (Sartorius) to monitor NK cell control of the ovarian cancer cell line SKOV-3 over the course of 6 days (Supplemental Figure 2B). We similarly observed no difference between control NK cells and *T+E* edited NK cells at early time points, but over the course of 6 days, *T+E* edited NK cells were unable to control SKOV-3 cells as effectively as control NK cells (Supplemental Figure 2B). This is consistent with the need to replenish cytotoxic effector proteins after initial preformed granules are depleted.

EOMES and T-BET are required for tumor control in vivo. To assess the impact of T-box TF deficiency on NK cells' ability to control tumor in vivo, we engrafted *TRAC* gRNA/CRISPR-edited (control NK), *TBX21*-edited, *EOMES*-edited, or *T+E* edited NK cells into NOD-*scid* IL2Rg^{null} (NSG) mice, which lack T, B, or NK cells and thus allow for xenograft of human cells (Figure 1E) (26). Recombinant human (rh) IL-15 was administered 3 times per week to support human NK cell survival. The NK cells were engrafted and allowed 4 days for T-BET and EOMES protein to be downregulated in vivo. The mice were then challenged with MHC-I-deficient K562-luciferase (K562-luc) tumor cells. Mice that received control NK cells had minimal bioluminescent imaging signals on day 7 and day 10 after tumor challenge, while mice that received *TBX21*- or *EOMES*-single-edited or *T+E* edited NK cells had significantly higher tumor burden than those that received control NK cells (Figure 1, F and G), indicating reduced NK cell antitumor response in the absence of T-BET and/or EOMES. While mice that received *TBX21*- or *EOMES*-single-edited NK cells still had significantly reduced tumor burden compared with mice that received no NK cells, mice that received *T+E* edited NK cells had an average tumor burden that was not significantly different from that of mice that did not receive NK cells (Figure 1G).

EOMES and T-BET are required for NK cell persistence and proliferation in vivo. We hypothesized that the significant defect in tumor control by *T+E* edited NK cells was due to reduced persistence or proliferation or decreased functionality of the DKO NK cells. To address these possibilities, the ability of NK cells to undergo homeostatic proliferation and persist in vivo without EOMES and T-BET was evaluated. *T+E* edited NK cells were engrafted into NSG mice, and 2–3 weeks later the number of NK cells in various tissues was determined (Figure 2A and Supplemental Figure 3A). Notably, on average at least 75% fewer *T+E* edited NK cells




Figure 1. EOMES and T-BET are required for optimal tumor control in vivo. (A) NK cells were subjected to electroporation to deliver Cas9 mRNA and sgRNAs. NK cells were cultured in low-dose (LD) IL-15, and on day 6/7, T-BET and EOMES protein expression was assessed by flow cytometry. LRS, leukocyte reduction system. (B) Representative flow plot of EOMES and T-BET protein expression in control NK cells and NK cells targeted simultaneously with *TBX21* and *EOMES* gRNAs (*T+E* edited). (C) Summary data of DKO efficiency in *T+E* edited NK cells. *n* = 10 donors, 9 independent experiments. (D) *T+E* edited NK cells were cultured in LD IL-15, then harvested on day 6/7, stained for annexin V and 7-aminoactinomycin D, and analyzed by flow cytometry. *n* = 4 donors, 4 independent experiments. (E) NK cells from either *TRAC* gRNA-edited (control), *TBX21*-edited, *EOMES*-edited, or *T+E* edited group were injected i.v. into NSG mice. Four days later, mice were challenged with luciferase-expressing K562 tumor cells. Injections of rhIL-15 i.p. were performed 3 times a week to support the human NK cells. (F) Representative bioluminescent imaging (BLI) of tumor burden in NSG mice that received no NK, control NK, or *TBX21*- and *EOMES*-edited NK cells. (G) Summary data of tumor burden measured by BLI. Two outliers in the control NK group were identified by ROUT (81) (*Q* = 0.1%) and excluded from the analysis. *n* = 6–9 mice each group, from 5 donors, 5 independent experiments. Data were compared using 2-way ANOVA in C and D, and mixed-effects analysis with Holm-Šidák multiple-comparison test in G. **P* < 0.05, ***P* < 0.01.

were recovered compared with control NK cells in all 3 tissues investigated: spleen, blood, and liver (Figure 2, B–D). Since *T+E* editing is not completely efficient, we expected the small fraction of *T-BET*⁺*EOMES*⁺ wild-type (WT) NK cells to have an expansion advantage *in vivo* over this time course. Consistent with this, intracellular flow cytometry staining revealed that the number of *T+E* edited NK cells that were deficient for both *T-BET* and *EOMES* (DKO) at the protein level was significantly reduced in frequency after *in vivo* proliferation for 2–3 weeks, in comparison with the *in vitro* day 7 expression (Figure 2E). While NK cells expressing WT levels of *EOMES* and *T-BET* within the *T+E* edited group were only a minority after 7 days *in vitro*, these WT NK cells became a majority of the NK cells recovered from mice that received *T+E* edited NK cells when assessed after 2–3 weeks (Figure 2E), providing further evidence that the DKO NK cells had a competitive disadvantage.

Since cell death was minimally impacted in *T+E* edited NK cells (Figure 1D), we hypothesized that *EOMES* and *T-BET* are required for NK cell homeostatic proliferation, and this mechanism explains the lower number of *T+E* edited NK cells recovered following engraftment into NSG mice. To assess *in vivo* proliferation, *T+E* edited NK cells were labeled with CellTrace Violet dye and transferred into NSG mice, and dye dilution was quantified by flow cytometry after 1.5–2 weeks (Figure 2F). The numbers of divisions that flow-gated *T-BET*⁻ and *EOMES*-WT, single-KO (Δ *T-BET* and Δ *EOMES*), and DKO NK cells underwent were assessed. While single *T-BET* or *EOMES* deletion resulted in impaired proliferation, deleting both *T-BET* and *EOMES* profoundly reduced proliferation (Figure 2, G and H). In fact, a majority of DKO NK cells did not proliferate, in contrast to almost all WT NK cells having divided at least once by this time (Figure 2H). This proliferation defect observed in DKO NK cells is consistent with the low numbers of NK cells recovered and the increase in the frequency of WT NK cells in the NK compartment from mice that received *T+E* edited NK cells (Figure 2, A–E).

Since it was previously reported in a murine NK cell study that NK cell proliferation can be regulated differentially at different states of maturation (27), we further categorized the human NK cells harvested from the NSG mice into human maturation stages, *CD57*⁺*NKG2A*⁺, *CD57*⁺*NKG2A*⁻, and *CD57*⁻*NKG2A*⁻, and assessed the effect of *EOMES* and *T-BET* deficiency on the proliferation of these specific subsets (Supplemental Figure 3B). DKO of *T-BET* and *EOMES* significantly reduced proliferation of all 3 subsets, while single deletion of *T-BET* or *EOMES* only reduced proliferation in the more mature *CD57*⁺ subsets (Supplemental Figure 3B).

EOMES and T-BET deletion impairs NK cell cytokine production. We next assessed the functionality of NK cells after they were CRISPR-edited to abrogate *T-BET* and *EOMES* expression. Whereas nearly all *in vivo*-transferred human NK cells recovered were *CD56*^{dim}, both *CD56*^{bright} and *CD56*^{dim} NK cell subsets were readily discernible *in vitro* (Supplemental Figure 1A and Supplemental Figure 3A). Based on the different functional characteristics of these subsets (28, 29), *CD56*^{bright} and *CD56*^{dim} NK cells were analyzed separately. CRISPR-edited NK cells were stimulated with K562 or cytokines (IL-12 and IL-15) and assessed for their ability to degranulate (surface *CD107a*) or produce immunomodulatory cytokines (IFN- γ and TNF), compared with control

NK cells (Figure 3, A–D, and Supplemental Figure 4, A–F). *TBX21* editing alone did not significantly affect NK cell function in this assay (Figure 3A and Supplemental Figure 4, A and B). *EOMES* editing alone only reduced *CD56*^{bright}, but not *CD56*^{dim}, NK cell IFN- γ production after stimulation by cytokines or K562 (Figure 3B and Supplemental Figure 4, C and D). Simultaneous deletion of *EOMES* and *T-BET* led to marked reduction of IFN- γ and TNF production in both *CD56*^{bright} and *CD56*^{dim} NK cells, even when the potent stimulating cytokine combination of IL-12, IL-15, and IL-18 was used (Figure 3, C and D, and Supplemental Figure 4, E and F). Notably, degranulation in response to K562 cells was not affected by genetic deletion (Supplemental Figure 4, E and F).

To give the effect of *T-BET* and *EOMES* deletion more time to manifest prior to assessment of these functions, we engrafted NSG mice with NK cells CRISPR-edited with *TBX21* and *EOMES* gRNAs and 1.5–2 weeks later assessed functionality *ex vivo* with isolated splenocytes. Here, intracellular flow gating was used to separately analyze NK cells that were Δ *T-BET* or Δ *EOMES* single KO or DKO at the protein level (Figure 3, E–H). Δ *T-BET* and Δ *EOMES* single-KO NK cells had significantly impaired IFN- γ and TNF production in response to cytokine stimulation compared with WT NK cells (Figure 3, F and G). However, like in the *in vitro* setting, degranulation was not significantly impacted with single *T-BET* or *EOMES* deletion alone (Figure 3H). DKO of both *T-BET* and *EOMES* resulted in marked reduction of NK cell function *ex vivo*: DKO NK cells had minimal production of IFN- γ and TNF in response to the potent combined cytokine stimulation of IL-12 plus IL-15 plus IL-18 (Figure 3, F and G). In contrast to the *in vitro* setting, NK cells lacking both *EOMES* and *T-BET* also had marked impairment of K562-induced degranulation (Figure 3H). These data demonstrate that both *EOMES* and *T-BET* are critical for primary NK cell degranulation and cytokine production upon stimulation with cellular targets or proinflammatory cytokines.

We also tested whether *T-BET*⁻ and *EOMES*-DKO NK cells could produce similar amounts of IFN- γ compared with control NK cells if we bypassed receptor signaling completely by using PMA and ionomycin to stimulate. Similar to responses following K562 or cytokine stimulation, PMA- and ionomycin-stimulated *T-BET*⁻ and *EOMES*-DKO NK cells were able to produce only minimal IFN- γ (Figure 3I).

EOMES and T-BET deletion impairs NK cell numbers and effector molecule expression at tumor sites. To assess the *in vivo* responses of *EOMES*⁻ and *T-BET*⁻ deficient NK cells, we followed the same experimental approach as in Figure 1E, but sacrificed K562-luc tumor-bearing mice 3 days after tumor injection to assess numbers and phenotypes of control versus *T-BET*⁻ and *EOMES*-DKO NK cells (Figure 4). At this time point, while *T+E* edited NK cells were able to traffic to the tumor-infiltrated lung and liver, *T+E* edited NK cell percentages and absolute numbers were reduced in comparison with control NK cells (Figure 4, A–C). In addition, *T-BET*⁻ and *EOMES*-DKO NK cells harvested from tumor-bearing organs had reduced IFN- γ , granzyme B, and perforin compared with WT NK cells (Figure 4D).

IL-15 and IL-12 receptor signaling responses are impacted by lack of T-BET and EOMES. Multiple signaling pathways downstream of the IL-15 receptor (IL-15R) impact NK cell functions, including survival, proliferation, cytokine production, and cytotoxicity (30).




Figure 2. EOMES and T-BET are required for NK cell persistence and proliferation in vivo. (A) Experimental schema for B–E. (B–D) Summary data of NK cell numbers recovered from indicated tissues of NSG mice that received control NK cells or T+E edited NK cells. *n* = 12–15 mice per condition, 6 donors, 5 independent experiments. (E) WT (T-BET⁺EOMES⁺), ΔT-BET (T-BET⁺EOMES⁺), ΔEOMES (T-BET⁺EOMES⁺), and DKO (T-BET⁺EOMES⁺) cells were identified by flow cytometry. Left: Representative flow plot. Right: Summary data of the percentage of each population within the NK compartment of indicated tissues of mice that received T+E edited NK cells. In vitro percentages were assessed about 1 week after electroporation. *n* = 3 donors, 3 independent experiments. (F) Schema for proliferation study. T+E edited NK cells were labeled with CellTrace Violet (CTV) dye before injection into NSG mice. (G and H) 1.5–2 weeks later, percentages of NK cells that had undergone the indicated number of divisions (G) and those that had not divided (H) were assessed by CTV dye dilution by flow cytometry. *n* = 3 donors, 5 mice, 3 independent experiments. Data were compared using unpaired *t* test in B–D and 2-way ANOVA with Holm–Šidák multiple-comparison test in E, G, and H. **P* < 0.05, ***P* < 0.01, *****P* < 0.0001.




Figure 3. EOMES and T-BET deletion impairs NK cell cytokine response. (A–D) In vitro functional assessment. Day 6/7 after CRISPR electroporation, NK cells were stimulated with K562 and IL-12+15. Degranulation (CD107a) and IFN-γ production were quantified by intracellular flow staining. (A–C) Summary data of IFN-γ response by *TBX21*-edited (A), *EOMES*-edited (B), and *T+E* edited (C) CD56^{bright} NK cells. (D) Summary data of IFN-γ response control and *T+E* edited NK cells stimulated with IL-12+15+18. *n* = 7–10 donors, 4–7 independent experiments in A–D. (E) Schema of ex vivo functional assessment experiment. 1.5–2 weeks after NK cell injection, splenocytes were harvested and stimulated with K562, IL-12+15, and IL-12+15+18 for 6 hours. (F–H) Summary data of IFN-γ (F), TNF (G), and CD107a (H) in human NK cells within indicated T-BET/EOMES flow gate. *n* = 2 donors, 4 mice, 3 independent experiments. (I) 1.5 weeks after CRISPR editing, in vitro-maintained NK cells were stimulated with PMA/ionomycin for 6 hours. IFN-γ production by NK cells by flow-gated CD56^{bright} and CD56^{dim} subsets is shown. *n* = 4 donors, 2 independent experiments. Data were compared by 2-way ANOVA with Holm-Šidák multiple-comparison test. **P* < 0.05, ***P* < 0.01, ****P* < 0.001, *****P* < 0.0001.

We hypothesized that signaling downstream of cytokine receptors may be defective in NK cells that lack T-BET and EOMES, thereby explaining their proliferative and functional defects. The NK cell response to IL-15R stimulation was assessed by measurement of phosphorylation of signaling intermediate proteins in pathways downstream of IL-15R (STAT5, ERK1/2 [MAPK], and AKT pathways) by flow cytometry upon IL-15 stimulation (Figure 5, A and B) (30). In both CD56^{bright} and CD56^{dim} NK cells, phosphorylation of STAT5 was unaltered, even in NK cells that lacked both T-BET and EOMES, consistent with their intact survival. However, phosphorylated ERK (p-ERK) was reduced in *TBX21*- or *EOMES*-sin-

gle-edited NK cells, and this defect was markedly more evident in *T+E* edited NK cells (Figure 5, A and B). p-AKT was only significantly decreased in *T+E* edited NK cells in both CD56^{bright} and CD56^{dim} subsets (Figure 5, A and B). The responsiveness of *TBX21*-, *EOMES*-, and *T+E* edited NK cells to IL-12R signaling was assessed by STAT4 phosphorylation (Figure 5C). p-STAT4 of CD56^{bright} NK cells was significantly impacted by deletion of one or both T-box TFs. p-STAT4 of CD56^{dim} NK cells followed the same trend, with statistically significant reduction in *TBX21*-edited and *T+E* edited NK cells, and a non-significant trend (*P* = 0.06) in *EOMES*-edited NK cells (Figure 5C).




Figure 4. Deletion of EOMES and T-BET impairs NK cell numbers and effector molecule expression in K562 tumor-bearing mice. NK cells from either *TRAC* gRNA-edited (control) NK group or *T+E* edited NK group were injected i.v. into NSG mice the day after electroporation, and i.p. injections of rhIL-15 were performed 3 times a week to support the human NK cells. Four days after NK injection, mice were challenged i.v. with $1.5 \times 10^6 \pm 0.1 \times 10^6$ luciferase-expressing K562 tumor cells. Three days after tumor injection, mice were imaged, and tumor-bearing tissues were harvested and assessed. **(A)** Representative BLI image of tumor signals. **(B and C)** Percent of lymphocyte gate (FSC by SSC) **(B)** and absolute NK cell number **(C)** in the livers and lungs of tumor-bearing mice. **(D)** Flow cytometry assessment of IFN- γ , granzyme B, and perforin expression in gated WT and DKO NK cells from the liver and lung of tumor-bearing mice that received *T+E* edited NK cells. Data were compared with Welch's *t* test in **B and C**, and 2-way ANOVA with Holm-Sidak multiple-comparison test in **D**. $n = 8-9$ mice per group, 4 donors, 4 independent experiments. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$.

Western blots of control, *TBX21*-edited, *EOMES*-edited, and *T+E* edited NK cell lysates show that total AKT, ERK1/2, and STAT4 proteins were not affected by T-BET or *EOMES* deletion, indicating that the observed differences in phosphorylated proteins were not due to decreases in total protein level of the specific signaling protein (Supplemental Figure 5, A and B; see complete unedited blots in the supplemental material). We also assessed the expression of the IL-15R subunit CD122 and found no significant differences between control and *T+E* edited NK cells maintained in vitro at the time point when the phosphorylation assay was performed 6 days after electroporation (Supplemental Figure 5C).

EOMES and T-BET are required to sustain the NK cell transcriptional program. As T-BET and *EOMES* primarily orchestrate gene transcription, we evaluated NK cell transcriptomes following T-BET and

EOMES deletion. Single-cell RNA-Seq (scRNA-Seq) (10x Genomics) was performed on *TRAC*-edited (control) and *T+E* edited NK cells. CRISPR-edited NK cells from each donor were transferred into NSG mice, followed by rhIL-15 support 3 times per week for survival. After 1 week, splenocytes of the NSG mice were isolated, and human NK cells were purified by flow sorting (mCD45⁺hCD45⁺hCD3⁺hCD56⁺, >98% purity; 3 donors in vivo). To provide an in vitro comparison to account for in vivo phenotypic changes, and to allow analysis of both CD56^{bright} and CD56^{dim} NK cell subsets, CRISPR-edited NK cells were cultured for 1 week in vitro in parallel (5 donors total in vitro). In vitro and in vivo data sets were analyzed separately, contrasting control-edited and *T+E* edited NK cells (Supplemental Figure 6A). This approach revealed distinct clusters of NK cells in uniform manifold approximation and projection (UMAP) space (Supplemental Figure 6, B and C).




Figure 5. Deletion of EOMES and T-BET impairs phosphorylation of ERK and AKT downstream of IL-15 signaling. NK cells were rested in cytokine-free medium for 1 hour before stimulation with the indicated concentrations of IL-15. Phosphorylated STAT5 (p-STAT5) was assessed in cells stimulated for 15 minutes, while p-ERK and p-AKT were assessed at 1 hour. **(A and B)** Summary data of MFI fold change of CD56^{bright} **(A)** and CD56^{dim} **(B)** NK cells. *n* = 3 donors, 3 independent experiments. **(C)** Summary data of STAT4 phosphorylation upon IL-12 stimulation. p-STAT4 was assessed in cells stimulated with IL-12 for 1 hour. *n* = 5–8 donors, 3–6 independent experiments. Data were compared with 2-way ANOVA with Holm-Šidák multiple-comparison test. **P* < 0.05, ***P* < 0.01, ****P* < 0.001, *****P* < 0.0001.

The single-cell sequencing approach allowed us to distinguish KO cells within the heterogeneous population of edited cells in the analysis. We first assigned *in vitro* clusters to be either CD56^{bright} or CD56^{dim} NK cells based on established scRNA-Seq expression patterns of markers for each subset (Supplemental Figure 6, B and C) (31, 32). Almost all NK cells recovered 1 week after transfer *in vivo* were CD56^{dim} NK cells, since all clusters expressed the CD56^{dim}

subset marker *FCGR3A* (CD16) (Supplemental Figure 6C). While EOMES and T-BET proteins are expressed by all conventional NK cells, their transcript levels are known to be relatively low and difficult to detect because of limitations in existing scRNA-Seq technology. Thus, we used the sample origin proportion of each cluster to identify the cells that were most likely to be T-BET- and EOMES-KO, as those cells would be unique to *T+E* edited samples




Figure 6. Single-cell RNA sequencing reveals transcriptional profile regulated by EOMES and T-BET in human NK cells. In vitro- and in vivo-maintained CRISPR-edited human NK cells were subjected to scRNA-Seq. Data shown are from pooled analysis of $n = 3$ –5 donors from 3–5 independent experiments. (A and B) UMAP of NK cells maintained in vitro (A) and in vivo (B), with control and KO clusters identified (see Methods and Supplemental Figure 6). (C and E) Expression level of selected DEGs overlaid on UMAP. (D and F) Violin plots of expression of selected DEGs in control and KO clusters. Wilcoxon's rank-sum test was used for differential analysis with a threshold of adjusted P value less than 0.05.

(Supplemental Figure 6, B and C, and see Methods). Notably, the majority of cells belonging to cycling clusters from both in vitro and in vivo originated from control samples, which is consistent with our experimental data demonstrating impaired proliferation of KO NK cells (Supplemental Figure 6, B and C, and Figure 2, F–H). Finally, we reclustered only the non-cycling control and KO clusters for visualization (Figure 6).

Differential expression analysis identified numerous genes that were downregulated in KO clusters, many of which were consistently downregulated across the 3 subsets: in vivo, in vitro CD56^{bright}, and in vitro CD56^{dim} NK cells (Figures 6 and 7, Supplemental Figure 7, and Supplemental Table 1). Genes responsible for various NK cell functions were altered in KO cells (Figure 6 and Figure 7, A and B). For example, genes that encode several cytotoxic granzymes and chemokines, including CCL5, secreted by NK cells to recruit other cells during an immune response, were also downregulated (33–35). Many NK cell trafficking regulators were downregulated in KO clusters as well, for example S1PR5, known to promote NK cell migration (17, 36). The gene expression of the granule protein NKG7, which regulates degranulation in NK cells,

was also reduced in KO clusters (37). The KO clusters did have significantly higher expression of some notable genes compared with control clusters, including TNFRSF18 (GITR), which has been shown to negatively regulate NK proliferation and activation (38–40). Increased expression of integrin ITGB7 was also observed in all 3 settings. We also observed a decrease in IL12RB2 transcript expression in KO clusters in in vitro CD56^{bright} and CD56^{dim} NK cells and in vivo (CD56^{dim}), which may mechanistically contribute to the decrease of p-STAT4 in response to IL-12 stimulation in NK cells that lack EOMES and T-BET (Figure 7A and Figure 5C).

We performed gene set enrichment analysis (GSEA) to assess Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment on control versus KO NK cell clusters, and in concordance with the individual genes we observed to be downregulated, the “natural killer cell mediated cytotoxicity” pathway was negatively enriched in KO cells from the in vitro as well as the in vivo samples (Figure 7, C and D). In agreement with the downregulated PRF1 and GZMB transcripts, a significant decrease in their protein expression was observed in DKO NK cells by flow cytometry (Supplemental Figure 8). These data reveal that T-BET and EOMES




Figure 7. EOMES and T-BET are required to sustain the NK cell transcriptional program. (A and B) Heatmap of selected DEGs within each subset identified by scRNA-Seq analysis of control and *T+E* edited NK cells in Figure 6. Wilcoxon’s rank-sum test was used for differential analysis with a threshold of adjusted *P* value less than 0.05. (C and D) Gene set enrichment analysis of the “NK cell mediated cytotoxicity” pathway from the KEGG database in KO versus control clusters.

exert a sustained and ongoing control of key human NK cell effector function mediator genes, and when T-BET and EOMES are deleted, these programs are rapidly curtailed.

Single knockout of T-BET or EOMES has a modest effect on human NK cell transcriptional profiles. To investigate the individual contribution of EOMES and T-BET to these changes, control, *TBX21*-edited, *EOMES*-edited, and *T+E* edited NK cells generated in vitro were compared. Control, *TBX21*-edited, and *EOMES*-edited samples had similar UMAP clustering, indicating that single *TBX21* or *EOMES* editing had minimal effect on major NK cell transcriptional profiles (Supplemental Figure 9, A–D). Comparing NK cells with single or double editing of T-box TFs against control samples with-

in CD56^{bright} and CD56^{dim} clusters, *T+E* edited NK cells had more differentially expressed genes (DEGs) than single-edited NK cells in comparison with control (Supplemental Figure 9, E–K). In this analysis, 375 of 527 DEGs identified of all comparisons belonged to the *T+E* edited samples compared against control and were not significant in single-edited sample comparisons — for example, *KLRD1* and *IL2RG* in CD56^{bright} clusters and *PRF1* and *SLAMF7* in CD56^{dim} clusters (Supplemental Figure 9, I–K). Some genes, like *NKG7* (CD56^{bright}), *GZMB* (both CD56^{bright} and CD56^{dim}), and *S1PR5* (CD56^{dim}), were downregulated by single deletion of either *TBX21* or *EOMES*, but the fold change over control was greater when both TFs were edited. *TBX21*-single-edited NK cells had the fewest




Figure 8. Loss of T-box TFs in NK cells results in ILC-3-biased ILC progenitor cell phenotype. (A) Heatmap of differentially expressed ILCP-associated marker genes expressed by in vitro CD56^{bright} KO versus control clusters. (B) UMAP of in vitro CD56^{bright} NK cells only. (C) UMAP overlaid with density of cells originating from control samples and T+E edited samples. (D) Violin plot of ILCP-related markers within clusters identified in B. (E) Expression of indicated ILCP-related markers overlaid on UMAP space. DEGs were determined using Wilcoxon’s rank-sum test and adjusted P value of less than 0.05. (F) Protein expression of CD117, NKp80, CD94, and NKG2D of in vitro-maintained TRAC-edited (control) and gated T-BET/EOMES-DKO cells 8 days after CRISPR electroporation quantified by flow cytometry. n = 4 donors, 2 independent experiments. Data were compared with ratio paired t test. *P < 0.05, **P < 0.01.

transcriptional changes (31 and 29 DEGs in CD56^{bright} and CD56^{dim}, respectively), while more genes — for example, *TNFRSF18* (CD56^{bright}) and *LYST* (CD56^{dim}) — were differentially expressed in *EOMES*-edited (113 and 48 DEGs in CD56^{bright} and CD56^{dim}, respectively) and T+E edited (336 and 304 DEGs in CD56^{bright} and

CD56^{dim}, respectively) NK cells but not in NK cells that were only *TBX21*-edited (Supplemental Figure 9, I–K). Since the effect of single *TBX21* or *EOMES* CRISPR editing on the transcriptional profile of NK cells was minimal, we focused subsequent analyses on control versus T+E edited NK cells.




Figure 9. EOMES and T-BET maintain NK cell chromatin accessibility. (A) Differentially accessible regions (DARs) identified by DESeq2 (blue, FDR > 0.05; pink, FDR ≤ 0.05). (B) HOMER de novo motif enrichment analysis on all DARs using findMotifsGenome.pl with automatically generated background by HOMER. (C) Square pie chart of genomic region distribution of all DARs annotated using ChIPseeker annotatePeak function. (D) Venn diagram of overlapping genes annotated as downregulated DARs in ATAC-seq and genes identified as downregulated DEGs in CD56^{bright} or CD56^{dim} KO clusters in scRNA-Seq. (E) Genomic region distribution of DARs (100 regions total, annotated to 82 unique genes) that are annotated to be in or near DEGs. (F) Representative peaks in *PRF1*, *S1PR5*, and *GZMM*, regions showing loss of accessibility in T+E edited NK cells. *n* = 2 donors, 2 independent experiments.

T-BET and EOMES regulate expression of other TFs. Among the significantly differentially expressed genes in the KO versus control clusters of T+E edited versus control NK cell samples, we identified TF genes implicated in lymphocyte and NK cell function and identity (Supplemental Figure 9). Expression of *ZEB2*, a known target of T-BET required for mouse NK cell terminal maturation, was significantly decreased in all 3 settings of in vitro CD56^{bright}, CD56^{dim},

and in vivo KO compared with control clusters (Supplemental Figure 10) (41). *RUNX3*, critical for innate lymphoid cell (ILC) lineage and function, and *BHLHE40* (a cofactor of T-BET), which promotes *IFNG* expression in lymphocytes, were downregulated in the KO clusters of in vitro CD56^{dim} and the in vivo set compared with control clusters (42–46). Two notable TF genes that were altered in KO NK cells in the in vivo setting are *NFATC2* and *KLF2* (Sup-

plemental Figure 10A). NFAT is induced upon activation of NK cells and promotes transcription of *IFNG* in NK cells (47). *KLF2*, a negative regulator of NK cell proliferation, was increased in KO clusters in vivo (Supplemental Figure 10A) (48). Interestingly *KLF2* expression was lower in the in vitro CD56^{bright} KO cluster compared with control (Supplemental Figure 10C). This demonstrates that the expression and regulatory contributions of TFs downstream of T-BET and EOMES are dependent on both NK subset and context.

In both in vitro CD56^{bright} and CD56^{dim} NK cells, *ETS1*, known for its essential role in NK cell development and in promoting *IFNG* expression, had reduced expression in the KO clusters (Supplemental Figure 10, B and C) (49–51). *BCL11B*, which is a key TF critical for human NK cells to differentiate from CD56^{bright} to CD56^{dim}, was also decreased in CD56^{dim} KO clusters (52).

Loss of T-box TFs results in ILC-3-biased ILC progenitor cells. NK cells and ILC-1s are categorized as group 1 ILCs. There are 2 other lineages of innate lymphocytes (ILC-2s and ILC-3s) that produce cytokines analogous to their helper T cell counterparts (53, 54). Accompanying the decreased expression of the T-box TFs that promote NK cell maturation, we observed an increased expression of TFs associated with ILC-3 identity in the KO cluster of in vitro CD56^{bright} NK cells. The expression of the ILC-3-defining TFs *AHR* and *RORC* was significantly higher in the KO compared with the control cluster, consistently across donors (Figure 8A) (54–57). This is in concordance with the increased expression of the immature NK cell/innate lymphocyte markers *KIT* and *IL23R* in these CD56^{bright} KO clusters (Figure 8A) (53, 54). *IKZF3* (AILOLOS) expression, which is normally suppressed in ILC-3s but expressed by NK cells, was also downregulated in CD56^{bright} KO clusters (58, 59). To investigate whether these markers are altered in all versus a subset of cells within the CD56^{bright} KO cluster, clustering and UMAP plotting were performed with only the CD56^{bright} KO and control clusters identified in Figure 6A (Figure 8, B–E). This revealed a cluster (cluster 4), predominantly composed of cells from the *T+E* edited samples, that highly expressed ILC-3-associated markers (Figure 8, D and E). The other cluster predominantly composed of the *T+E* edited NK cells (cluster 1) shared high expression of *KIT* and decreased expression of *KLRD1* and *KLRF1* similar to those in cluster 4. Taking into consideration that the NK cells used in this study were derived from peripheral blood, cluster 1 and cluster 4 (which expressed ILC-3 transcripts) appear most similar to CD117⁺CD56⁺ ILC precursors (ILCPs) that can give rise to both NK cells and ILC-3s, since fully mature ILC-3s are predominantly tissue-resident (60, 61). We validated increased protein expression of CD117, encoded by *KIT*, as well as decreased protein expression of CD94, Nkp80, and NKG2D in DKO CD56^{bright} NK cells by flow cytometry, consistent with the expression patterns of these molecules at the ILCP stage of NK development (Figure 8F) (60). These data suggest that T-BET and EOMES are required to actively suppress alternative ILC lineage-defining programs in CD56^{bright} NK cells, and when these T-box TFs are removed, NK cells become ILCP-like and can acquire genes associated with a different ILC lineage.

T-BET and EOMES regulate chromatin accessibility in human NK cells. As T-box TFs have been suggested to act as pioneer factors that can modulate chromatin accessibility, we hypothesized that loss of T-BET and EOMES in mature NK cell subsets conse-

quently results in epigenetic remodeling (16, 62–64). Assay for transposase-accessible chromatin using sequencing (ATAC-seq) was performed on control and *T+E* edited NK cells, to elucidate the impact of T-BET and EOMES deletion on chromatin accessibility. Consistent with our hypothesis, chromatin accessibility was decreased in many genomic regions in the *T+E* edited compared with control NK cells (Figure 9A and Supplemental Table 2). Motif analysis revealed significant enrichment of T-box family motifs within loci that had reduced accessibility in *T+E* edited NK cells. Further, ETS and RUNX motifs were also enriched in these regions, suggesting that T-BET, EOMES, RUNX3, and ETS1 together likely coordinate a large component of the human NK cell molecular program (Figure 9B). Differentially accessible regions (DARs) identified were distributed mainly in introns (44.6%), distal intergenic regions (26.3%), and promoter regions (21.6%) (Figure 9C). Many DARs that were less accessible in *T+E* edited NK cells were in or near DEGs that were decreased in KO clusters (CD56^{bright} and/or CD56^{dim}) identified from the scRNA-Seq data (Figure 7 and Figure 9D). The 100 DARs (annotated to 82 unique genes) that overlapped with DEGs were distributed in genomic regions similarly to all the DARs identified (Figure 9E). As examples, decreased peak signals were identified in putative regulatory regions and promoter regions of *PRF1*, *SIPR5*, and *GZMM* whose transcript expression levels were decreased in KO clusters of the scRNA-Seq experiment (Figure 7, Figure 9F, and Supplemental Figure 7). This suggests that T-BET and EOMES maintain accessibility of critical regulatory regions of genes, thereby sustaining the NK cell transcriptional program.

Discussion

In this paper, we report that ongoing transcriptional regulation by T-BET and EOMES is required for proper function of mature human NK cells. Deletion of both EOMES and T-BET resulted in reduced ability of human NK cells to control tumor targets in vivo. Mechanistically, this is explained by reduced proliferation, impaired cytokine-receptor signaling, and defective NK cell effector functions. Cytokine production was reduced when NK cells lacked one or both TFs. T-BET- and EOMES-DKO cells produced almost no IFN- γ and had compromised IL-15 and IL-12 receptor signaling. NK cells lacking both T-BET and EOMES also had reduced degranulation to tumor targets after a more prolonged time period following the CRISPR deletion. Further, T-BET and EOMES single deletion had differential effects on the function of CD56^{bright} and CD56^{dim} NK cell subsets, suggesting both redundant and unique regulatory roles in an NK cell subset-specific fashion. Finally, by scRNA-Seq analysis, NK cells demonstrated a profound loss of the NK cell functional and identity-defining transcriptional programs, as well as the unexpected emergence of an ILC-3-biased ILCP molecular program. Collectively, these findings demonstrate that EOMES and T-BET are required for fully developed NK cells to properly respond to stimuli, as well as to maintain NK cell identity.

The role of EOMES and T-BET in initiation of NK cell development is well established in mouse models. Mice with global knockout of T-BET lack mature NK cells in the periphery (15, 16). Similarly, in hematopoietic compartment-specific and constitutive NK cell-specific EOMES-KO mouse models, mature NK cell numbers

are markedly reduced (15, 65). Likewise, the importance of T-BET in human NK cell development was evidenced by a patient with T-BET deficiency, who had an impaired group 1 ILC compartment (20). Forced overexpression of T-BET and EOMES can accelerate *in vitro* NK cell differentiation from cord blood, but these studies do not inform their requirement for maintenance of mature NK cell function or molecular program (23). Collectively, these published studies have defined the clear requirement for T-box TFs to *initiate* NK cell molecular programs, as they develop from multipotential progenitors. However, these models are generally not sufficient to understand the ongoing importance of, and genetic programs sustained by, T-box TFs, which dynamically alter expression levels during NK cell maturation (27).

Recently, our group developed an inducible NK cell-specific EOMES KO mouse model that revealed the requirement of sustained EOMES expression for proper murine NK cell effector functions and the homeostasis of stage II and III murine NK cells (18). This contrasts with the EOMES-deleted human NK cells reported here, where human NK cell subset-specific functions are minimally affected, without impacting NK cell survival. Based on these observations, the study of T-box TFs within human NK cells is required to understand their role in human NK cell molecular programs. Here, we show that single deletion had modest impact on human NK cell functions and transcriptional profile compared with double T-BET and EOMES deletion. These findings contrast with mouse studies showing functional defects and widespread transcriptional changes in T-BET- or EOMES-single-KO NK cells. This again highlights distinctions between murine and human NK cell transcriptional control (18, 66). Moreover, there have been no murine studies of simultaneous T-BET and EOMES conditional and inducible deletion to date. Our data demonstrate that T-BET and EOMES exhibit redundancy in human NK cells in terms of functional regulation as well as transcriptional regulation. Thus, our finding that EOMES and T-BET are of profound and critical importance for ongoing human NK cell functions and identity provides important new insights into the NK cell molecular program, including key downstream TFs impacted by EOMES and T-BET regulation.

scRNA-Seq analysis of CRISPR-edited primary human NK cells revealed EOMES and T-BET regulated key NK cell functional pathway genes, including cytotoxic effector molecules, NK cell receptors, and trafficking and migration regulators (e.g., chemokines and chemokine receptors). Using a loss-of-function approach, several TFs were discovered to be directly regulated by T-BET and EOMES, many of which have roles in regulating *IFNG* transcription in other cell types. For example, in both CD56^{bright} and CD56^{dim} T-BET- and EOMES-KO human NK cells, a reduced expression of ZEB2 was observed, which is a direct target of T-BET in mouse NK cells and is required for mouse NK cells to mature and acquire optimal function (41). Moreover, T-BET- and EOMES-KO NK cells have reduction of RUNX3, which has been shown to be critical for ILC lineage initiation, cytotoxic molecule expression, and IL-15-induced proliferation (42–44). Further, BHLHE40, a cofactor of T-BET that normally promotes *IFNG* expression in lymphocytes, also had markedly decreased expression in DKO human NK cells (45, 46). The downregulation of ETS1 in DKO NK clusters likely contributed to the reduction of IFN- γ upon IL-12 stimulation in *T+E* edited NK cells (49–51). Collectively, the approach of T-box TF deletion followed by analysis of

RNA expression in single cells reveals critical links between T-BET, EOMES, and these transcriptional regulators, providing evidence of their ongoing regulation by T-box TFs in human NK cells.

In the more immature CD56^{bright} NK cell compartment, we observed a reversion of NK cells to have ILCP-like marker expression pattern and an ILC-3-biased ILCP population that was specifically enriched in the T-BET- and EOMES-KO samples. This cluster resembles the previously described CD56⁺ ILCPs in its high expression of CD117 and IL23R (60). Consistent with the description that the CD56⁺ ILCPs can give rise to group 1 and group 3 ILCs, this ILCP-like cluster observed in our study seems to be biased toward the ILC-3 lineage with its high expression of the ILC-3-associated TFs RORC and AHR and low expression of IKZF3 (58, 61). This observation is also consistent with functional plasticity between ILC groups, in this case mature human NK cells and ILCPs, governed by expression levels of ILC group-specific TFs (58, 65, 67). Our data suggest that EOMES and T-BET suppress non-NK ILC lineages, with a bias specifically against the ILC-3 lineage, and when EOMES and T-BET are deleted, NK cells acquire a transcriptional signature that matches that of an ILC-3-biased ILCP.

This study also revealed that T-BET and EOMES not only regulate transcript expression in NK cells, but also participate in maintaining chromatin accessibility. Abrogation of T-BET and EOMES led to decreased chromatin accessibility near the *PRF1* and *SIPR5* loci, both of which had decreased transcript expression in *T+E* edited NK cells, among many other NK cell effector function-related gene loci that were also transcriptionally affected. The reduced chromatin accessibility upon T-box TF deletion indicates an active role in maintaining the NK cell state, and reveals a new layer of regulation by T-BET and EOMES beyond transcriptional regulation, as they are critical for NK cell chromatin states.

NK cellular therapy is a promising cancer immunotherapy, since tumor cells commonly express NK-activating ligands as well as downregulate MHC class I molecules, which render them sensitive to NK cell-mediated clearance (3, 4). Expression of T-BET and EOMES is negatively regulated by immunosuppressive cytokines like TGF- β in tumors (68, 69). In a mouse adoptive transfer model, reduced EOMES and T-BET expression over time in NK cells after adoptive transfer correlated with reduced IFN- γ production and impaired long-term tumor control (70). Our loss-of-function study showed that T-BET and EOMES in mature NK cells are indeed required for NK cell function, and thus reduction of T-box TFs directly limits NK cell functional capacity. As our study focused on conventional, peripheral blood NK cells, future work should investigate the expression and importance of T-BET and EOMES in various NK therapeutic approaches such as cord blood-derived NK cells, induced pluripotent stem cell-derived NK cells, cytokine-induced memory-like NK cells, and NK cells transduced with chimeric antigen receptors (5, 12, 71–74). The expression levels and kinetics of T-BET and EOMES in those settings could be potentially utilized as a measure of NK cell identity integrity and optimal function.

In summary, this study reveals that EOMES and T-BET are required for sustaining mature NK cell identity and functional activity. The deletion of EOMES and T-BET led to functional, proliferative, and signaling defects that resulted in an impaired response against tumor cells *in vivo*. This illustrates the importance

of maintaining T-BET and EOMES expression for optimal NK cell antitumor responses. Moreover, deletion of these NK cell identity TFs results in emergence of an ILC-3–biased ILCP program that may represent a default developmental pathway. Future studies that interrogate the role of genes that are directly regulated by T-BET and EOMES revealed in our study, and that are indirectly regulated through other TFs regulated by T-BET and EOMES, will be important steps to further elucidate how NK cells orchestrate a transcription network responsible for mature NK cell responses.

Methods

Human NK cell isolation and culture. Healthy donor NK cells were isolated from leukapheresis chamber from platelet donors using RosetteSep (STEMCELL Technologies) (routinely >95% CD56⁺CD3⁻) followed by Ficoll-Paque PLUS (GE Healthcare) centrifugation. NK cells were maintained in low-dose (1–3 ng/mL) IL-15 in RPMI 1640 plus 10% heat-inactivated human AB serum plus 10 mM HEPES plus 1× penicillin/streptomycin plus 1% of non-essential amino acids, sodium pyruvate, and L-glutamine as previously described (9), with media changes every other day.

Mice. NOD-*scid* IL2Rg^{null} (NSG) mice were purchased from The Jackson Laboratory (RRID:IMSR_JAX:005557). Mice were then bred and maintained in specific pathogen-free housing, and experiments were conducted in accordance with the guidelines of and with the approval of the Washington University Animal Studies Committee. Experiments were performed on 7- to 16-week-old male and female mice. Within each experiment, mice were age and sex matched.

Cell lines. K562 cells were obtained from ATCC and authenticated in 2015 by SNP analysis. K562 cells were cultured in RPMI 1640 medium plus 10% heat-inactivated FBS plus 10 mM HEPES plus 1× penicillin/streptomycin plus 1% of non-essential amino acids, sodium pyruvate, and L-glutamine.

CRISPR editing of human NK cells. Freshly isolated NK cells were rested in low-dose IL-15 (1–3 ng/mL) overnight. The next day, NK cells were harvested, washed with PBS, and resuspended in MaxCyte EP Buffer at concentrations recommended by the manufacturer. Cas9 mRNA and gRNA were introduced into the NK cells by electroporation using the protocol WUSTL-2 on the MaxCyte GT electroporation machine. Cells were incubated for 10 minutes at 37°C immediately after electroporation. Low-dose IL-15 medium was added after the incubation. Media changes were performed every 2–3 days. Synthetic sgRNAs were produced by Synthego with modifications (2'-O-methyl at first 3 and last bases and 3' phosphorothioate bonds between first 3 and last 2 bases). The sgRNA sequences were as follows: *EOMES*, AACAGTATTAGGAGACTCT; *TBX21*, CACCACTGGCGGTACCA-GAG; *TRAC*, GAGAATCAAAATCGGTGAAT.

Apoptosis assessment. On day 6/7 after CRISPR electroporation, NK cells were harvested and assessed for apoptosis using annexin V and 7-aminoactinomycin D (Sigma-Aldrich) in 1× Annexin V Binding Buffer (Thermo Fisher Scientific) after surface marker staining for flow cytometry analysis.

NSG xenograft and tumor model. The next day after CRISPR electroporation, 1 × 10⁶ NK cells were washed with PBS and injected into NSG mice i.v.; the cells were then supported with 1 μg rhIL-15 i.p. 3 times per week. For K562 tumor challenge experiments, approximately 1.5 × 10⁶ luciferase-expressing K562 cells were injected i.v. 4 days after NK cell injection, and 100 ng/mouse

rhIL-15 was used to support NK cells for the duration of the experiment after tumor injection. Bioluminescent imaging (BLI) was performed twice a week on an AMI imager (Spectral Instruments Imaging) 10 minutes after i.p. injection of 150 mg/kg D-luciferin. Quantification of BLI signals was performed using Aura software (Spectral Instruments Imaging).

For proliferation assessment, NK cells were washed with PBS and incubated with 1:2,000 CellTrace Violet (Invitrogen) following the manufacturer's protocol for labeling before injection into the mice. Dye dilution was tracked at time of mouse harvesting by flow cytometry.

For experiments assessing persistence, proliferation, and ex vivo functionality, NK cells were maintained with 1 μg/mouse rhIL-15 i.p. 3 times per week for the entire course of the study.

Flow cytometry. Surface marker staining was performed in PBS plus 1 mM EDTA plus 2% heat-inactivated FBS at 4°C in the presence of heat-inactivated goat serum (Sigma-Aldrich). Mouse F_c-Block (BD Biosciences) was also used in NSG mice experiments. Intracellular staining was performed with the eBioscience FoxP3 staining kit following the manufacturer's protocol. Antibodies used are listed in Supplemental Methods. Data were acquired on Beckman Coulter Gallios and Thermo Fisher Scientific Attune flow cytometers and analyzed using FlowJo (Tree Star).

Phospho-signaling assessment. On day 6/7 after CRISPR electroporation, NK cells were harvested from tissue culture plates, and cytokine-containing medium was washed off and replaced with cytokine-free medium. NK cells were rested in cytokine-free medium for 30 minutes up to 2 hours. In each experiment an equal number of NK cells, up to 200,000 NK cells, were plated for each condition. Then IL-15 and IL-12 were used to stimulate NK cells (timing and concentration are indicated in figure legends). At the end of incubation, NK cells were fixed with prewarmed 1% paraformaldehyde and permeabilized using ice-cold methanol. Cells were washed 3 times with FACS buffer before staining with surface markers and phospho-antibodies overnight at 4°C.

Assessment of degranulation and cytokine production. For in vitro-maintained cells, unless otherwise indicated, on day 6/7 after electroporation up to 200,000 NK cells were plated in 1 well of a 96-well U-bottom plate for each condition. In each independent experiment, an equal number of NK cells were plated for all samples. Stimulation conditions were as follows: K562 at the ratio of 5 NK to 1 K562; 5 ng/mL IL-12 + 25 ng/mL IL-15; 5 ng/mL IL-12 + 25 ng/mL IL-15 + 5 ng/mL IL-18. Immediately after stimulation began, anti-CD107a antibody was added to all wells of the assay. After 1 hour, GolgiPlug and GolgiStop (BD Biosciences) were added and the assay was incubated for 5 hours more, for a total of 6 hours. Then flow cytometry staining was performed as described above to assess intracellular IFN-γ and TNF.

Ex vivo assessment was performed similarly but with isolated splenocytes 1.5–2 weeks after injection of NK cells into NSG mice. Stimulation conditions were as follows: K562 at the ratio of 10 splenocytes to 1 K562; 20 ng/mL IL-12 + 100 ng/mL IL-15; 20 ng/mL IL-12 + 100 ng/mL IL-15 + 20 ng/mL IL-18.

For PMA/ionomycin stimulation experiments, NK cells were stimulated with 1× eBioscience Cell Stimulation Cocktail. After 2 hours, GolgiPlug and GolgiStop were added and the assay was incubated for 4 hours more, for a total of 4 hours. Then flow cytometry staining was performed as described above to assess intracellular IFN-γ.

Single-cell RNA-Seq. For each donor, live human NK cells (Zombie mCD45⁺hCD45⁺hCD3⁺CD56⁺) were sorted from splenocytes of NSG mice 7 days after injection using the BD FACSAria Cell Sorter (>98% purity). In parallel, NK cells that were injected into NSG mice were also cultured in vitro in 1 ng/mL IL-15, harvested, and subjected to flow sorting at the same time as the in vivo-maintained human NK cells followed by 10x Genomics scRNA-Seq (5' v2 chemistry). The resulting data were analyzed as previously described using Cell Ranger (v6.0, 10x Genomics) with genome alignment to GRCh38; downstream analysis was performed using Seurat v4 (10, 11). Detailed quality control and filtering steps are described in Supplemental Methods.

Resulting clusters were first assigned to be CD56^{bright} or CD56^{dim} and cycling clusters, where cells have high expression of S phase- and G₂M phase-associated genes. Then clusters were grouped into the following: “KO,” non-cycling clusters where more than 75% of cells within the cluster originate from T+E edited samples; and “control,” non-cycling clusters where fewer than 75% of cells are T+E edited samples. “Control” and “KO” clusters were then reclustered for visualization. Differential gene expression analysis was performed using Wilcoxon's rank-sum test implemented in the Seurat FindMarkers function (parameters: logfc.threshold = 0.25, min.pct = 0.1). Gene set enrichment analysis was performed using the R package clusterProfiler (75).

Assay for transposase-accessible chromatin using sequencing. CRISPR-edited NK cells were harvested from tissue culture plates on day 7 and day 10 after CRISPR electroporation. Nuclei and libraries were prepared for assay for transposase-accessible chromatin using sequencing (ATAC-seq) following established protocol using Illumina kits (76). The samples from the 2 time points were treated as technical replicates in the analysis using standard ATAC-seq analysis pipeline and tools. Briefly, paired-end reads were trimmed for adaptors and low-quality reads were removed using Cutadapt (v3.2) (77). Trimmed reads were aligned to the *Homo sapiens* genome assembly hg38 using Bowtie2 (v2.4.1) (78, 79). Samtools (v1.3.1) (80) was used to filter reads by alignment score and remove mitochondrial reads, and PCR duplicates were removed using Picard (v2.25.0) (<https://broadinstitute.github.io/picard/>). Peak calling was performed using Genrich (v0.6) (<https://github.com/jsh58/Genrich>) ATAC-seq mode (-j -d 100). Differential accessibility analysis was determined by DESeq2 using DiffBind (v4.2) and annotated using ChIPseeker (v1.28.3) R packages. De novo motif enrichment analysis on all differentially accessible genomic regions was performed with HOMER (v4.11) using findMotifsGenome.pl with automatically generated background by HOMER.

Data availability. The scRNA-Seq (GEO GSE227636) and ATAC-seq (GEO GSE227878) data were deposited to the NCBI's Gene Expression Omnibus database (GEO). No new code was generated in this study; all analyses were performed using existing packages. Specific parameters used to analyze the data are indicated in Methods and Supplemental Methods.

Statistics. Statistical comparisons were performed as indicated in each figure using GraphPad Prism (v9) software or in R. Data are represented as mean ± SEM, and all significance testing comparisons are 2-sided. The specific statistical tests and the sample size are indicated in the respective figure legends. $P < 0.05$ was considered statistically significant.

Study approval. All animal studies were approved by the Washington University IACUC and experiments were conducted in accordance with the guidelines of and with approval by the Washington University Animal Studies Committee.

Author contributions

PW and TAF conceptualized the project. PW, JAF, MMBE, and TAF developed the methodology. PW, JAF, LC, CCN, TY, CCC, JT, SKS, SP, NJ, DARG, NDM, M Gang, JAW, AYZ, MTJ, MF, TS, LM, EM, PP, MBH, BF, AAP, OLG, M Griffith, and MMBE performed the investigation and formal analysis. PW and TAF wrote the original draft of the manuscript. All authors wrote, reviewed, and edited the manuscript.

Acknowledgments

We acknowledge the Siteman Flow Cytometry Core, the Genome Technology Access Center at the McDonnell Genome Institute, and the Genome Engineering and IPSC Center at Washington University School of Medicine. Schemata were created using BioRender (biorender.com). This work was supported by NIH/National Heart, Lung, and Blood Institute T32HL007088 (to PW, JAF, JAW, and DARG), NIH/National Institute of Allergy and Infectious Diseases F30AI161318 (to CCC), NIH/National Institute of General Medical Sciences (NIGMS) F31GM146361-01 (to JT), NIH/NIGMS T32GM139799 (to JAF), NIH/National Cancer Institute (NCI) Leukemia SPORE P50CA171063 (to TAF and MMBE), NIH/NCI R01CA205239 (to TAF), NIH/NCI Cancer Center Support Grant P30CA91842 (to TAF), and NIH/NCI U01CA248235 (to M Griffith); the American Association of Immunologists Intersect Fellowship Program for Computational Scientists and Immunologists (to JAF and TAF); Conquer Cancer, the ASCO Foundation, Young Investigator Award (to MTJ and DARG); a Kenneth Rainin Foundation Innovator Award (to NJ); a Washington University McDonnell Genome Institute Pilot Grant (to TAF); the Alvin J. Siteman Cancer Center Siteman Investment Program (supported by the Foundation for Barnes-Jewish Hospital, Cancer Frontier Fund, and Barnard Trust) (to TAF and OLG); and the Paula C. and Rodger O. Riney Blood Cancer Research Initiative Fund (to TAF).

Address correspondence to: Todd A. Fehniger, Washington University School of Medicine in St. Louis, 660 S. Euclid Avenue, Campus Box 8007, St. Louis, Missouri 63110, USA. Phone: 314.362.5654; Email: tfehniger@wustl.edu.

- Vivier E, et al. Functions of natural killer cells. *Nat Immunol.* 2008;9(5):503–510.
- Caligiuri MA. Human natural killer cells. *Blood.* 2008;112(3):461–469.
- Gang M, et al. Memory-like natural killer cells for cancer immunotherapy. *Semin Hematol.* 2020;57(4):185–193.
- Shimasaki N, et al. NK cells for cancer immunotherapy. *Nat Rev Drug Discov.* 2020;19(3):200–218.
- Romee R, et al. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. *Sci Transl Med.* 2016;8(357):357ra123.
- Berrien-Elliott MM, et al. Allogeneic natural killer cell therapy. *Blood.* 2023;141(8):856–868.
- Cichocki F, et al. Engineered and banked iPSCs for advanced NK- and T-cell immunotherapies. *Blood.* 2023;141(8):846–855.
- Mehta RS, et al. Cord blood as a source of natural killer cells. *Front Med (Lausanne).* 2016;2:93.
- Berrien-Elliott MM, et al. Multidimensional analyses of donor memory-like NK cells reveal new associations with response after adoptive immunotherapy for leukemia. *Cancer Discov.* 2020;10(12):1854–1871.
- Bednarski JJ, et al. Donor memory-like NK cells persist and induce remissions in pediatric

- patients with relapsed AML after transplant. *Blood*. 2022;139(11):1670-1683.
11. Berrien-Elliott MM, et al. Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia. *Sci Transl Med*. 2022;14(633):eabm1375.
 12. Liu E, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. *N Engl J Med*. 2020;382(6):545-553.
 13. Knox JJ, et al. Characterization of T-bet and Eomes in peripheral human immune cells. *Front Immunol*. 2014;5:217.
 14. Simonetta F, et al. T-bet and eomesodermin in NK cell development, maturation, and function. *Front Immunol*. 2016;7:241.
 15. Gordon SM, et al. The transcription factors T-bet and Eomes control key checkpoints of natural killer cell maturation. *Immunity*. 2012;36(1):55-67.
 16. Townsend MJ, et al. T-bet regulates the terminal maturation and homeostasis of NK and Valpha14i NKT cells. *Immunity*. 2004;20(4):477-494.
 17. Jenne CN, et al. T-bet-dependent SIP5 expression in NK cells promotes egress from lymph nodes and bone marrow. *J Exp Med*. 2009;206(11):2469-2481.
 18. Wagner JA, et al. Stage-specific requirement for Eomes in mature NK cell homeostasis and cytotoxicity. *Cell Rep*. 2020;31(9):107720.
 19. Adams NM, et al. Cutting edge: heterogeneity in cell age contributes to functional diversity of NK cells. *J Immunol*. 2021;206(3):465-470.
 20. Yang R, et al. Human T-bet governs innate and innate-like adaptive IFN- γ immunity against mycobacteria. *Cell*. 2020;183(7):1826-1847.
 21. Putz EM, et al. Targeting cytokine signaling checkpoint CIS activates NK cells to protect from tumor initiation and metastasis. *Oncimmunology*. 2017;6(2):e1267892.
 22. Huang RS, et al. Enhanced NK-92 cytotoxicity by CRISPR genome engineering using Cas9 ribonucleoproteins. *Front Immunol*. 2020;11:1008.
 23. Kiekens L, et al. T-BET and EOMES accelerate and enhance functional differentiation of human natural killer cells. *Front Immunol*. 2021;0:3741.
 24. Zhang J, et al. T-bet and Eomes govern differentiation and function of mouse and human NK cells and ILC1. *Eur J Immunol*. 2018;48(5):738-750.
 25. Yang Y, et al. T-bet and eomesodermin play critical roles in directing T cell differentiation to Th1 versus Th17. *J Immunol*. 2008;181(12):8700-8710.
 26. Shultz LD, et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. *J Immunol*. 2005;174(10):6477-6489.
 27. Zhang J, et al. Sequential actions of EOMES and T-BET promote stepwise maturation of natural killer cells. *Nat Commun*. 2021;12(1):5446.
 28. Cooper MA, et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56 (bright) subset. *Blood*. 2001;97(10):3146-3151.
 29. Nagler A, et al. Comparative studies of human FcR3-positive and negative natural killer cells. *J Immunol*. 1989;143(10):3183-3191.
 30. Mishra A, et al. Molecular pathways: interleukin-15 signaling in health and in cancer. *Clin Cancer Res*. 2014;20(8):2044-2050.
 31. Smith SL, et al. Diversity of peripheral blood human NK cells identified by single-cell RNA sequencing. *Blood Adv*. 2020;4(7):1388-1406.
 32. Crinier A, et al. High-dimensional single-cell analysis identifies organ-specific signatures and conserved NK cell subsets in humans and mice. *Immunity*. 2018;49(5):971-986.
 33. Trapani JA. Granzymes: a family of lymphocyte granule serine proteases. *Genome Biol*. 2001;2(12):REVIEWS3014.
 34. Böttcher JP, et al. NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. *Cell*. 2018;172(5):1022-1037.
 35. Robertson MJ. Role of chemokines in the biology of natural killer cells. *J Leukoc Biol*. 2002;71(2):173-183.
 36. Drouillard A, et al. S1PR5 is essential for human natural killer cell migration toward sphingosine-1 phosphate. *J Allergy Clin Immunol*. 2018;141(6):2265-2268.
 37. Ng SS, et al. The NK cell granule protein NKG7 regulates cytotoxic granule exocytosis and inflammation. *Nat Immunol*. 2020;21(10):1205-1218.
 38. Buechele C, et al. Glucocorticoid-induced TNFR-related protein (GITR) ligand modulates cytokine release and NK cell reactivity in chronic lymphocytic leukemia (CLL). *Leuk*. 2011;26(5):991-1000.
 39. Liu B, et al. Glucocorticoid-induced tumor necrosis factor receptor negatively regulates activation of human primary natural killer (NK) cells by blocking proliferative signals and increasing NK cell apoptosis. *J Biol Chem*. 2008;283(13):8202-8210.
 40. Baltz KM, et al. Cancer immunoeediting by GITR (glucocorticoid-induced TNF-related protein) ligand in humans: NK cell/tumor cell interactions. *FASEB J*. 2007;21(10):2442-2454.
 41. van Helden MJ, et al. Terminal NK cell maturation is controlled by concerted actions of T-bet and Zeb2 and is essential for melanoma rejection. *J Exp Med*. 2015;212(12):2015-2025.
 42. Ebihara T, et al. Runx3 specifies lineage commitment of innate lymphoid cells. *Nat Immunol*. 2015;16(11):1133.
 43. Cruz-Guilloty F, et al. Runx3 and T-box proteins cooperate to establish the transcriptional program of effector CTLs. *J Exp Med*. 2009;206(1):51-59.
 44. Levanon D, et al. Transcription factor Runx3 regulates interleukin-15-dependent natural killer cell activation. *Mol Cell Biol*. 2014;34(6):1158-1169.
 45. Kanda M, et al. Transcriptional regulator Bhlhe40 works as a cofactor of T-bet in the regulation of IFN- γ production in iNKT cells. *Proc Natl Acad Sci U S A*. 2016;113(24):E3394-E3402.
 46. Uyeda MJ, et al. BHLHE40 regulates IL-10 and IFN- γ production in T cells but does not interfere with human type 1 regulatory T cell differentiation. *Front Immunol*. 2021;12:2705.
 47. Tassi I, et al. NK cell-activating receptors require PKC-theta for sustained signaling, transcriptional activation, and IFN-gamma secretion. *Blood*. 2008;112(10):4109-4116.
 48. Rabacal W, et al. Transcription factor KLF2 regulates homeostatic NK cell proliferation and survival. *Proc Natl Acad Sci U S A*. 2016;113(19):5370-5375.
 49. Barton K, et al. The Ets-1 transcription factor is required for the development of natural killer cells in mice. *Immunity*. 1998;9(4):555-563.
 50. Taveirne S, et al. The transcription factor ETS1 is an important regulator of human NK cell development and terminal differentiation. *Blood*. 2020;136(3):288-298.
 51. Grenningloh R, et al. Ets-1, a functional cofactor of T-bet, is essential for Th1 inflammatory responses. *J Exp Med*. 2005;201(4):615-626.
 52. Holmes TD, et al. The transcription factor Bcl11b promotes both canonical and adaptive NK cell differentiation. *Sci Immunol*. 2021;6(57):eabc9801.
 53. Mjösberg J, Spits H. Human innate lymphoid cells. *J Allergy Clin Immunol*. 2016;138(5):1265-1276.
 54. Huang Q, et al. Shaping innate lymphoid cell diversity. *Front Immunol*. 2017;8:1569.
 55. Hughes T, et al. The transcription factor AHR prevents the differentiation of a stage 3 innate lymphoid cell subset to natural killer cells. *Cell Rep*. 2014;8(1):150-162.
 56. Mjösberg J, et al. Transcriptional control of innate lymphoid cells. *Eur J Immunol*. 2012;42(8):1916-1923.
 57. Scoville SD, et al. A progenitor cell expressing transcription factor ROR γ t generates all human innate lymphoid cell subsets. *Immunity*. 2016;44(5):1140-1150.
 58. Cella M, et al. Subsets of ILC3-ILC1-like cells generate a diversity spectrum of innate lymphoid cells in human mucosal tissues. *Nat Immunol*. 2019;20(8):980-991.
 59. Holmes ML, et al. Peripheral natural killer cell maturation depends on the transcription factor Aiolos. *EMBO J*. 2014;33(22):2721-2734.
 60. Chen L, et al. CD56 expression marks human group 2 innate lymphoid cell divergence from a shared NK cell and group 3 innate lymphoid cell developmental pathway. *Immunity*. 2018;49(3):464-476.
 61. Björklund ÅK, et al. The heterogeneity of human CD127(+) innate lymphoid cells revealed by single-cell RNA sequencing. *Nat Immunol*. 2016;17(4):451-460.
 62. Lewis MD, et al. T-bet's ability to regulate individual target genes requires the conserved T-box domain to recruit histone methyltransferase activity and a separate family member-specific transactivation domain. *Mol Cell Biol*. 2007;27(24):8510-8521.
 63. Istaces N, et al. EOMES interacts with RUNX3 and BRG1 to promote innate memory cell formation through epigenetic reprogramming. *Nat Commun*. 2019;10(1):1-17.
 64. Agarwal P, et al. Gene regulation and chromatin remodeling by IL-12 and type I IFN in programming for CD8 T cell effector function and memory. *J Immunol*. 2009;183(3):1695-1704.
 65. Pikovskaya O, et al. Cutting edge: Eomesodermin is sufficient to direct type 1 innate lymphocyte development into the conventional NK lineage. *J Immunol*. 2016;196(4):1449-1454.
 66. Cuff AO, et al. Tbet promotes CXCR6 expression in immature natural killer cells and natural killer cell egress from the bone marrow. *Immunology*. 2020;161(1):28-38.

67. Colonna M. Innate lymphoid cells: diversity, plasticity, and unique functions in immunity. *Immunity*. 2018;48(6):1104–1117.
68. Ghiringhelli F, et al. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. *J Exp Med*. 2005;202(8):1075–1085.
69. Viel S, et al. TGF- β inhibits the activation and functions of NK cells by repressing the mTOR pathway. *Sci Signal*. 2016;9(415):ra19.
70. Gill S, et al. Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells. *Blood*. 2012;119(24):5758–5768.
71. Miller JS, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. *Blood*. 2005;105(8):3051–3057.
72. Cichocki F, et al. ARID5B regulates metabolic programming in human adaptive NK cells. *J Exp Med*. 2018;215(9):2379–2395.
73. Gang M, et al. CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas. *Blood*. 2020;136(20):2308–2318.
74. Zhu H, et al. Metabolic reprogramming via deletion of CISH in human iPSC-derived NK Cells promotes in vivo persistence and enhances anti-tumor activity. *Cell Stem Cell*. 2020;27(2):224–237.
75. Yu G, et al. clusterProfiler: an R package for comparing biological themes among gene clusters. *OMICS*. 2012;16(5):284–287.
76. Buenrostro JD, et al. Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. *Nat Methods*. 2013;10(12):1213–1218.
77. Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. *EMBnet.journal*. 2011;17(1):10–12.
78. Langmead B, et al. Scaling read aligners to hundreds of threads on general-purpose processors. *Bioinformatics*. 2018;35(3):421–432.
79. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. *Nat Methods*. 2012;9(4):357–359.
80. Li H, et al. The Sequence Alignment/Map format and SAMtools. *Bioinformatics*. 2009;25(16):2078–2079.
81. Motulsky H, Brown RE. Detecting outliers when fitting data with nonlinear regression — a new method based on robust nonlinear regression and the false discovery rate. *BMC Bioinformatics*. 2006;7:123.